# Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients

> **NCT02904031** · PHASE2 · UNKNOWN · sponsor: **Gruppo Oncologico del Nord-Ovest** · enrollment: 180 (estimated)

## Conditions studied

- Elderly Metastatic Colorectal Cancer Patients

## Interventions

- **DRUG:** 5-fluorouracil
- **DRUG:** oxaliplatin
- **DRUG:** l-leucovorin
- **DRUG:** panitumumab

## Key facts

- **NCT ID:** NCT02904031
- **Lead sponsor:** Gruppo Oncologico del Nord-Ovest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-07
- **Primary completion:** 2019-11-15
- **Final completion:** 2020-10
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2020-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02904031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02904031, "Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02904031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*